Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced a final cash dividend of RMB 2.5 per 10 shares for the financial year ending December 31, 2024. The dividend will be paid on July 22, 2025, following shareholder approval on May 22, 2025. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders, potentially impacting its market position positively.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of heparin products and other pharmaceutical services. The company is known for its significant role in the global supply of heparin, a critical anticoagulant used in medical treatments.
YTD Price Performance: 17.17%
Average Trading Volume: 3,044,091
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.52B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.